Search
News Archive
Categories
Archive for May, 2010
Enzymotec Krill Oil Product Gains Novel Food Approval in Europe
Posted On: May 26, 2010Enzymotec has announced that its leading product, Krill Oil +, has now obtained a Novel Food status in Europe for its Krill Product line , including the Pure Krill oil grade.
Recently the company announced the expansion of its product line into a greater variety of Krill-based combination products, including Krill-based variety of grades, Krill/PS combos and more.
“Enzymotec supports Krill sustainability and an eco-friendly supply chain aimed to maintain the conservation of marine living resources by sourcing its Krill biomass only from CCAMLR Member monitored vessels and facilities. Says Mrs. Neta Scheinman Enzymotec’s Director of QA. “We are inspecting and verifying that each Krill shipment is harvested within the limits of the zone and dates for which the specific fishing vessels had received it’s fishing license from CCALMR”, concludes Mrs. Scheinman.
Novel process allows ‘highest quality’ omega-3 concentrations
Posted On: May 26, 2010Novel technology allows KD-Pharma, the fully-owned subsidiary of health care products company Bioseutica, to produce what it claims to be the market’s safest and highest quality omega-3 concentrations.
Specific combinations of omega-3 EPA/DHA at concentrations of up to 99 percent are produced by the process, known as kd pür, which was designed, developed and patented the company.
This is achieved by advanced super critical fluid technology conducted under mild temperatures below 45 Celsius and under CO2 atmospheric conditions to extract, refine and concentrate highly purified omega-3s from fish oil.
The process is also said to remove other undesired components from omega-3s such as omega-6, saturated fats, cholesterol and contaminants.
Aker Biomarine’s Krill Fisheries Receives Marine Stewardship Council Certification
Posted On: May 26, 2010Aker BioMarine has today received confirmation that its krill fisheries will be certified by the Marine Stewardship Council (MSC), an independent, global, non-profit organization that works to promote the best choices in sustainable seafood.
In future purchases of Aker BioMarine’s Superba(tm) and Qrill(tm) products, consumers can be assured that their Omega-3 rich krill products are harvested in an environmentally sustainable way.
MSC’s fishery certification program contributes to the health of the world’s oceans by recognizing and rewarding sustainable fishing practices, influencing the choices people make when buying seafood and working with partners to transform the seafood market to a sustainable basis. The MSC certification is a visible demonstration of Aker BioMarine’s long term commitment to the environment.
Korea to explore ocean for future natural resources, including efforts to foster a marine biotechnology sector
Posted On: May 26, 2010South Korea imports most of its energy needs from outside, leaving itself extremely vulnerable to sudden changes in the price of oil and other raw materials.
Coupled with the rapid depletion of natural resources, surging demand from China, India and other fast-growing emerging economies raises the price of crude and other commodities sharply, weighing heavily on the Korean economy.
To secure a stable supply of energy resources and achieve a sustainable growth, the nation should turn its eye to the sea and make larger investments to explore a range of minerals on the sea bottom, Korea Ocean Research and Development Institute (KORDI) President Kang Jung-keuk stressed.
The institute is undertaking several economic feasibility studies on the construction of electric power plants using tidal currents in the West Sea, while working on the state-of-the-art technologies to produce bio-ethanol from marine algae.
`Generating electricity from tidal currents and extracting fuel from marine plants are environmentally friendly and renewable energies, which will help Korea reduce its imports of conventional fossil fuels, boost economic activities and create jobs. We will also make effort to foster a marine biotechnology sector by studying microorganisms that inhabit the most extreme living environments under the sea. By examining them, we could obtain materials for new medicines and create a range of benefits for humans,” Kang said.
Euromares 2010, held recently in Spain — results in advancement of marine and maritime policies of the EU
Posted On: May 21, 2010The latest advances and emerging ideas in the field of marine research, maritime innovation and the evaluation of the marine medium were at the forefront of the debates in the conference Euromares 2010, held from 18 to 19 May in Guijon, Spain.
Some 200 scientists, managers, politicians, authorities related to research and planning of the marine medium, NGO, the maritime industry and leaders of the maritime industry of all the Member States of the European Union (EU) participated in the event.
Bioprocessing Data for the Production of Marine Enzymes Now Available
Posted On: May 21, 2010Abstract: This review is a synopsis of different bioprocess engineering approaches adopted for the production of marine enzymes. Three major modes of operation: batch, fed-batch and continuous have been used for production of enzymes (such as protease, chitinase, agarase, peroxidase) mainly from marine bacteria and fungi on a laboratory bioreactor and pilot plant scales. Submerged, immobilized and solid-state processes in batch mode were widely employed. The fed-batch process was also applied in several bioprocesses. Continuous processes with suspended cells as well as with immobilized cells have been used. Investigations in shake flasks were conducted with the prospect of large-scale processing in reactors.
Trius Therapeutics Awarded U.S. Department of Defense Contract to Develop Novel Antibiotics from Marine Natural Product Libraries
Posted On: May 21, 2010Trius Therapeutics, Inc. today that it has been awarded a new four and a half year contract from the Defense Threat Reduction Agency (DTRA), an agency within the U.S. Department of Defense, for the development of novel antibiotics directed against gram-negative bacterial pathogens. Trius may receive up to $29.5 million in support of development efforts under the new DTRA contract, which is funded as part of DTRA’s Transformational Medical Technologies Initiative (TMTI). Pursuant to the contract, Trius will apply its proprietary Focused Antisense Screening Technology (FAST) discovery platform to identify the targets of antibacterial compounds from marine natural product libraries developed in the laboratory of Dr. William Fenical, Distinguished Professor of Oceanography at Scripps Institution of Oceanography at UC San Diego.
Trius will then apply its structure-based drug design and development capabilities in an effort to optimize promising antibacterial compounds for activity against gram-negative biodefense pathogens such as Yersinia pestis, Francisella tularensis and Burkholderia pseudomallei. Trius believes that these compounds will also be active against gram-negative pathogens involved in common hospital acquired infections.
Aqua Bio Tech Signs Major Supply Development Agreements
Posted On: May 17, 2010Aqua Bio Technology ASA (ABT), a marine biotechnology and ingredient company, signed two major supply and development agreements. The first agreement is with Bioforskning AS to supply ABT’s patented bioactive ingredient Zonase X™, an ingredient with origins from salmon hatching fluid for use in Bioforskning’s Skin Science professional skincare line. ABT has also secured a major supply and development deal with a global market leader in the health care sector.
Biofoskning’s Skin Science is an exclusive skincare line sold in the Scandinavian professional skincare market. Bioforskning AS is currently preparing a sales expansion of their Skin Science line to several major European markets during the second half of 2010, in addition to developing new lines of products incorporating ingredients such as ABT’s Zonase X, which will be launched during the second half of 2010 and first half 2011.
ABT’s supply and development agreement with the global health care company, who does not wish to be disclosed at this time for strategic reasons, involves development of new products based on certain components contained in ABT’s patented Zonase technology, including Zonase X. The agreement represents a breakthrough for ABT’s new ingredient technology and has significant commercial potential for the company, as it comprises development of products outside of the original application areas of Zonase (which include exfoliation, moisturization and rejuvenation of skin), proving the versatility of the Zonase X technology. A patent application has been filed securing both parties’ common commercial rights within the new product area.
Carlson Laboratories Introduces Liquid CalaOmega from Calamari
Posted On: May 14, 2010Carlson Laboratories is proud to introduce Liquid CalaOmega, its newest Norwegian marine oil. Liquid CalaOmega from calamari oil is naturally rich in DHA. Although both DHA and EPA provide cardiovascular benefits, DHA is almost exclusively the only omega-3 fatty acid in our brains and eyes. Unlike most harvested marine life, the DHA levels in calamari oil are over twice as high as the EPA levels making it a preferred source. Liquid CalaOmega provides 800 mg of DHA and 400 mg of EPA per delicious lemon-flavored teaspoon.
Unigen and University of Prince Edward Island Embark on Major Scientific Marine Collection Project
Posted On: May 14, 2010Unigen Pharmaceuticals, Inc., a leading natural products R&D company and proprietary rights supplier, and the University of Prince Edward Island (UPEI), have announced a partnership, which is the first step in an exciting process of collecting marine organisms from the Atlantic Ocean, with an eye to screening the samples for creating therapeutic and commercial products.
Unigen has been collecting plants and other organisms since 1997. Their research and discovery includes extensive work at both the human cell and gene level. Unigen focuses on identifying and studying the unique ingredients of medicinal botanicals and then developing proprietary raw materials for use in cosmeceutical, nutraceutical, functional food and pharmaceutical products. However, the current project will be the first time the company has developed a marine collection.
Researchers anticipate collecting a diverse range of marine organisms – invertebrates such as sponges, corals (non-reef builders), tunicates, and echinoderms, as well as algae, all of which will provide a wealth of information that will lead to discoveries of new chemical entities and novel natural, therapeutic commercial products.
Leading the collection process is Dr. Russell Kerr, Canada Research Chair in Marine Natural Products at UPEI. Dr. Kerr has been collecting and studying specimens in the Florida Keys and the Bahamas for over 20 years.
Host
 |
Partners
  |
Sponsors
 |
 |
Share Aquapreneur
